@article{edb9f08d2bda495bb61a96a6f1517a8f,
title = "Rules of engagement: Promoting academic-industry partnership in the era of digital pathology and artificial intelligence",
abstract = "Academic industry partnership (AIP) represents an important alliance between academic researchers and industry that helps translate technology and complete the innovation cycle within academic health systems. Despite diverging missions and skillsets the culture for academia and industry is changing in response to the current digital era which is spawning greater collaboration between physicians and businesses in this marketplace. In the field of pathology, this is further driven by the fact that traditional funding sources cannot keep pace with the innovation needed in digital pathology and artificial intelligence. This concept article from the Digital Pathology Association (DPA) describes the rules of engagement for pathology innovators in academia and for their corporate partners to help establish best practices in this critical area. Stakeholders include pathologists, basic and translational researchers, university technology transfer and sponsored research offices, as well as industry relations officers. The article discusses the benefits and pitfalls of an AIP, reviews different partnership models, examines the role of pathologists in the innovation cycle, explains various agreements that may need to be signed, covers conflict of interest and intellectual property issues, and offers recommendations for ensuring successful partnerships.",
keywords = "Academic-industry partnership, Artificial intelligence, Conflict of interest, Digital pathology, Industry, Innovation, Intellectual property, Patent, Sponsored research, University",
author = "Liron Pantanowitz and Bui, {Marilyn M.} and Chhavi Chauhan and Ehab ElGabry and Lewis Hassell and Zaibo Li and Parwani, {Anil V.} and Salama, {Mohamed E.} and Sebastian, {Manu M.} and David Tulman and Suryanarayana Vepa and Becich, {Michael J.}",
note = "Funding Information: Marilyn M. Bui is an employee of the H. Lee, Moffitt Cancer Center and Research Institute. She received a Cancer Center Support Grant from NIH as the Scientific Director of the Analytic Microscopy Core of Moffitt Cancer Center. She received US patents (No. 14/373,277 and No. 15/034,683). She received an honorarium serving on the medical/scientific advisory board of ContextVision, Visiopharm, and AstraZeneca. She donated her honorarium serving as the scientific advisory board of Aiforia to a pathology foundation. Funding Information: Michael J. Becich is a founder and equity owner in SpIntellx and has industry sponsored research agreements with Owkin, Inc. and Pfizer. Dr. Becich is a paid consultant to the following academic medical centers and cancer centers: Indiana University, Medical College WI, Northwestern University, Rockefeller University, Rutgers, UC Davis, UCSD, University of Chicago, University of Cincinnati, University of IL Chicago, University of New Mexico, USC, UTSA, University WI/Marshfield Clinic, Wake Forest Baptist Cancer Center. He receives federal funding from CDC NIOSH, NCATS and PCORI. Dr. Becich is an NIH employee as a member of the NCI Board of Scientific Advisors and the Frederic National Labs NCI/DOE Advisory Committee. Funding Information: David Tulman is a founder, equity owner, and board member of Instapath. Dr. Tulman receives federal funding from the NSF and state funding from the Cancer Prevention Research Institute of Texas. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = jan,
doi = "10.1016/j.acpath.2022.100026",
language = "English (US)",
volume = "9",
journal = "Academic Pathology",
issn = "2374-2895",
publisher = "SAGE Publications Ltd",
number = "1",
}